Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
James C Smith is Director at Pfizer. OQRO lists 5 transactions filed with the SEC under this name, the latest on Sep 29, 2026, each linked to the official Form 4.
Director
Disclosures on record
5
Companies involved
1
PfizerPFE
5 disclosures · Jan 2026 – Sep 2026
Sep 25, 20261,569.59disclosed Sep 29
DetailsOfficial recordJun 26, 20261,852.61disclosed Jun 30
DetailsOfficial recordApr 23, 20267,686.54disclosed Apr 27
DetailsOfficial recordMar 27, 20261,664.2disclosed Mar 31
DetailsOfficial recordDec 31, 20251,807.23disclosed Jan 5
DetailsOfficial recordJames C Smith bought shares on the open market in 2016, and has not bought since 2016. Sales in 1 of the 11 years since 2016.
James C Smith reported 1 open-market purchase and 1 sale since 2016; purchases in 2016.
| Year | Bought | Sold |
|---|---|---|
| 2016 | $51K1×1 trade | $7771×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
James C Smith bought shares on the open market in 2016, and has not bought since 2016. Sales in 1 of the 11 years since 2016.
In SEC filings since 2016: the latest open-market purchase is from 2016; the latest open-market sale is from 2016.
Pfizer (PFE), from 2016 to 2016: 1 purchase and 1 sale.
James C Smith reported 1 open-market purchase and 1 sale here, 2016.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.